Clinical Trial Update: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis [Phase 3]

View source ↗

Summary

BEKINDA (ondansetron 24 mg bimodal release tablets) was studied in a Phase 3 trial for vomiting due to presumed acute gastroenteritis or gastritis. The study ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastritis
• Gastroenteritis

Drugs mentioned

• BEKINDA (ondansetron)

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Gastroenteritis, Gastritis | Phase 3 | Status: COMPLETED | Results posted: 2019-02-20